Home > Products > Featured products

Lavendustin C (HDBA)

  Cat. No.:  DC10596   Featured
Chemical Structure
125697-93-0
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
Get Quotation Now
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
HDBA, a derivative of a Streptomyces griseolavendus butyl acetate extract, is a potent inhibitor of epidermal growth factor (EGF) receptor-associated tyrosine kinase with an IC50 value of 0.012 µM.
Chemicals PropertiesBiological activity COA & MSDSRelated productsDatasheet
Cas No.: 125697-93-0
Chemical Name: 5-(2,5-Dihydroxybenzylamino)-2-hydroxybenzoic Acid
Synonyms: 5-(2,5-Dihydroxybenzylamino)-2-hydroxybenzoic Acid;Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-;Lavendustin c;COMPOUND 5;HDBA;N-(2-((2-((4Z,7Z,10Z,13Z,16Z,19Z)-DOCOSA-4,7,10,13,16,19-HEXAENAMIDO)ETHYL)DISULFANYL)-2-METHYLPROPYL)NICOTINAMIDE;NSC 666251;Lavendustin C (HDBA);5-(2,5-DIHYDROXYBENZYLAMINO)SALICYLIC ACID;5-(N-2,5-DIHYDROXYBENZYL)AMINOSALICYLIC ACID;5-(N-2',5'-DIHYDROXYBENZYL)AMINOSALICYLIC ACID;N-(2',5'-DIHYDROXYBENZYL)-5-AMINOSALICYLIC ACID;2-hydroxy-5-(2,5-dihydrobenzyl)aminobenzoic acid
SMILES: C1=CC(=C(C=C1NCC2=CC(=CC=C2O)O)C(=O)O)O
Formula: C14NO5H13
M.Wt: 275.2567
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Lavendustin C is a potent Ca2+ calmodulin-dependent kinase II (CaMK II) inhibitor with an IC50 of 0.2 µM. Lavendustin C inhibits EGFR-associated tyrosine kinase (IC50=0.012 µM) and pp60c-src(+) kinase (IC50=0.5 µM) [1][2]..
In Vitro: Lavendustin C (Compound 5) shows potent inhibitory activity, and it may be the core structure responsible for inhibition of tyrosine kinase[1]. Lavendustin C (10-150 µM) inhibits tyrosine kinase-associated neutrophil degranulation and superoxide generation[3].
References: [1]. T Onoda, et al.Isolation of a Novel Tyrosine Kinase Inhibitor, Lavendustin A, From Streptomyces Griseolavendus. J Nat Prod. Nov-Dec 1989;52(6):1252-7. [2]. T J O'Dell, et al.Long-term Potentiation in the Hippocampus Is Blocked by Tyrosine Kinase Inhibitors. Nature. 1991 Oct 10;353(6344):558-60. [3]. H M Burt, et al. Inhibition of Crystal-Induced Neutrophil Activation by a Protein Tyrosine Kinase Inhibitor. J Leukoc Biol. 1994 Jan;55(1):112-9.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC70520 JBJ-09-063 JBJ-09-063 is a potent, mutant-selective allosteric EGFR inhibitor against EGFR L858R, T790M and C797S mutations, with IC50 of <0.1 nM for recombinant EGFR L858R/T790M kinase domain.
DC40932 JCN037 JCN037 (JGK037) is non-covalent and BBB-penetrant EGFR tyrosine kinase inhibitor, with IC50 values of 2.49 nM, 3.95 nM, 4.48 nM for EGFR, p-wtEGFR and pEGFRvⅢ, respectively.
DC7622 BIBX1382 BIBX 1382 is a potent, selective inhibitor of EGFR tyrosine kinase (IC50 = 3 nM); displays > 1000-fold lower potency against ErbB2 (IC50 = 3.4 μM) and a range of other related tyrosine kinases (IC50 > 10 μM).
DC12161 TAS6417 TAS6417 is an EGFR inhibitor and an efficacious drug candidate for patients with NSCLC, with IC50 values ranging from 1.1-8.0 nM.
DC10764 Theliatinib (HMPL-309) Theliatinib (HMPL-309) is a novel small molecule, EGFR tyrosine kinase inhibitor with potential antineoplastic and anti-angiogenesis activities.
DC5090 WZ4002 WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM; does not inhibit ERBB2 phosphorylation (T798I).
DC9775 WZ3146 WZ3146 is a mutant-selective irreversible inhibitor of EGFR(L858R) and EGFR(E746_A750) with IC50 of 2 nM and 2 nM; does not inhibit ERBB2 phosphorylation (T798I).
DC10519 SU 5214 SU 5214 is a modulator of tyrosine kinase signal transduction.
DC7078 AZD-8931(Sapitinib) Sapitinib(AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM respectively.
DC10479 RX518(CK-101:EGFR-IN-3) RX518(CK-101) is an orally available third-generation and selective inhibitor of certain epidermal growth factor receptor (EGFR) activating mutations.
X
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Site Map|Privacy PolicyCopyright © 2018-2020 All Rights Reserved. Technical Support:KuuJia